Andrew Ko, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Andrew Ko, MD

Associate Professor, Department of Medicine (Hematology/Oncology), UCSF

Phone: (415) 353-9888 (appts)
Box 1705, UCSF
San Francisco, CA 94143-1705

View on UCSF Profiles

Cancer Center Membership

Program Member » Developmental Therapeutics

Research Summary

My primary clinical and research interests focus on gastrointestinal malignancies, where I have developed and led multiple clinical trials, both within UCSF and across multiple sites nationwide and overseas. I am interested in the development and evaluation of new therapeutic agents ranging from novel cytotoxics to molecular targeted agents to immunotherapies, with a particular emphasis on evaluating these in patients with pancreatic cancer. This work has entailed collaborating with laboratory-based investigators on the correlative/translational science to identify individual patient/tumor characteristics that influence prognosis and response to specific therapies, including both tissue- and blood-based biomarkers. Other university responsibilities include leading the site committee for gastrointestinal cancer-specific clinical trial development at the UCSF HDFCCC and serving as chair of the scientific Protocol Review Committee. Nationally, I have served on the scientific program committee, grants committee, and specialty editorial board for the American Society of Clinical Oncology (ASCO), sit on the editorial board for multiple peer-reviewed oncology journals, and am currently a member of NCI’s Pancreatic Cancer Task Force and the NCCN Pancreatic Cancer guidelines committee.

Education

Brown University, Providence, RI, Sc.B., 1991, Applied Mathematics/Biology
Johns Hopkins School of Medicine, Baltimore, MD, M.D., 1995, Medicine
Board certified, Internal Medicine, 1998
Board certified, Medical Oncology, 2002


Professional Experience

  • 1995-1996
    Beth Israel Hospital (Boston, MA), intern, Department of Internal Medicine
  • 1996-1998
    Beth Israel Hospital (Boston, MA), resident, Department of Internal Medicine
  • 1998-2001
    Stanford University School of Medicine, fellow, Division of Medical Oncology
  • 2001-present
    University of California at San Francisco, Clinical Instructor, Division of Hematology/Oncology
  • 2003-2009
    University of California at San Francisco, Assistant Clinical Professor, Division of Hematology/Oncology
  • 2009-present
    University of California at San Francisco, Associate Professor of Clinical Medicine, Division of Hematology/ Oncology

Honors & Awards

  • 1987
    National Merit Scholarship
  • 1988
    IBM Thomas J. Watson Memorial Scholarship
  • 1990
    Sigma Xi, elected associate member
  • 1991
    Departmental honors and Magna cum laude, Brown University
  • 1993
    Alpha Omega Alpha, student essay competition honoree
  • 1994
    Harry C. Saltzstein Prize in Medical Writing, Johns Hopkins School of Medicine
  • 1995
    Medical Assistance Programs/Reader's Digest International Fellowship
  • 2000
    Amgen National Oncology Fellows' Forum, selected for oral presentation
  • 2000
    American Society of Clinical Oncology, Travel Award (meritorious abstract)
  • 2001
    Digestive Disease Center Collaborative Postdoctoral Fellowship
  • 2003
    UCSF Cancer Center Clinical Investigator Research Program award
  • 2003
    American Society of Clinical Oncology Career Development Award
  • 2007
    Joan Rombauer UCSF Endowed Fellowship
  • 2008
    UCSF Kaiser Award for Excellence in Teaching in the Classroom Setting, nominee
  • 2011
    NCI Cancer Clinical Investigator Team Leadership Award
  • 2013
    UCSF Hematology and Oncology Division Teaching Award

Selected Publications

  1. A MULTICENTER, OPEN-LABEL PHASE II CLINICAL TRIAL OF COMBINED MEK PLUS EGFR INHIBITION FOR CHEMOTHERAPY-REFRACTORY ADVANCED PANCREATIC ADENOCARCINOMA. Clin Cancer Res. 2015 Aug 6.
    View on PubMed
  2. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8.
    View on PubMed
  3. Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am. 2015 Aug; 29(4):741-59.
    View on PubMed
  4. Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. J Clin Oncol. 2015 Jun 1; 33(16):1779-86.
    View on PubMed
  5. Statin use and risk of pancreatic cancer: Results from a large, clinic-based case-control study. Cancer. 2015 Apr 15; 121(8):1287-94.
    View on PubMed
  6. Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. Am Soc Clin Oncol Educ Book. 2015; 35:e222-7.
    View on PubMed
  7. A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer. J Gastrointest Oncol. 2014 Dec; 5(6):E88-95.
    View on PubMed
  8. Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study. Int J Cancer. 2015 Mar 15; 136(6):E646-53.
    View on PubMed
  9. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014 Aug; 12(8):1083-93.
    View on PubMed
  10. Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor. Anticancer Res. 2014 Jul; 34(7):3629-34.
    View on PubMed
  11. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014 Jun; 45(2):168-80.
    View on PubMed
  12. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43(3):343-9.
    View on PubMed
  13. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer. 2014 Jun 15; 120(12):1780-6.
    View on PubMed
  14. Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? World J Gastroenterol. 2014 Mar 7; 20(9):2224-36.
    View on PubMed
  15. Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw. 2014 Feb; 12(2):167-72.
    View on PubMed
  16. Expanding options for pancreatic cancer... so where do we go from here? Oncology (Williston Park). 2014 Jan; 28(1):5.
    View on PubMed
  17. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 1; 109(7):1725-34.
    View on PubMed
  18. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Mol Cancer Ther. 2013 Oct; 12(10):2213-25.
    View on PubMed
  19. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013 Aug 20; 109(4):920-5.
    View on PubMed
  20. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-7.
    View on PubMed

Go to UCSF Profiles, powered by CTSI